CD160 and Graves disease: Graves’ Disease (Hirata et al., 2019), HIV Set Point Viral Load (Luo et al., 2021), Asthma (Sakaue et al., 2021), Psoriasis (Stuart et al., 2022), Plasma Protein Levels of AMBP, C2, CD160, CD28, CD48, CFB, FCRL1, FCRL6, FRZB, GP1BB, LILRB1, LTA, LY96, NID1, SIGLEC9, SORT1, THBD, TNFRSF4, TNFSF13B, TNXB, TP53BP1, VCAM1 (Krishna et al., 2024)